Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Gwyn Bebb

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
JTO Clinical and Research Reports|December 8, 2021
A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in CanadaAnifat A Elegbede, Amanda J Gibson, Andrea S Fung, et al.
Molecular Cancer Therapeutics|February 4, 2010
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitorsChris T Williamson, Huong Muzik, Ali G Turhan, et al.
Micron (Oxford, England : 1993)|August 25, 2014
Digital differentiation of non-small cell carcinomas of the lung by the fractal dimension of their epithelial architectureLik Hang Lee, Mauro Tambasco, Shannon Otsuka, et al.
Plos One|January 28, 2021
CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patientsAndrea S Fung, Karen Kopciuk, Michelle L Dean, et al.
Metabolomics : Official Journal of the Metabolomic Society|April 14, 2016
Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatmentDesirée Hao, M Omair Sarfaraz, Farshad Farshidfar, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based studyAmanda J W Gibson, Haocheng Li, Adrijana D'Silva, et al.
The Oncologist|September 30, 2024
Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancerJaime Shaw, Xerxes Pundole, Akhila Balasubramanian, et al.
Medical Oncology (Northwood, London, England)|August 4, 2018
Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancerAmanda Jane Williams Gibson, Haocheng Li, Adrijana D'Silva, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2024
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world studyHossein Borghaei, Xerxes Pundole, Laura Sangaré, et al.
British Journal of Cancer|April 19, 2020
Correction: Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cellsNicholas R Jette, Suraj Radhamani, Greydon Arthur, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
JTO Clinical and Research Reports|December 8, 2021
A Real-World Evaluation of Atezolizumab Plus Platinum-Etoposide Chemotherapy in Patients With Extensive-Stage SCLC in CanadaAnifat A Elegbede, Amanda J Gibson, Andrea S Fung, et al.
Molecular Cancer Therapeutics|February 4, 2010
ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitorsChris T Williamson, Huong Muzik, Ali G Turhan, et al.
Micron (Oxford, England : 1993)|August 25, 2014
Digital differentiation of non-small cell carcinomas of the lung by the fractal dimension of their epithelial architectureLik Hang Lee, Mauro Tambasco, Shannon Otsuka, et al.
Plos One|January 28, 2021
CXCR4 expression in lung carcinogenesis: Evaluating gender-specific differences in survival outcomes based on CXCR4 expression in early stage non-small cell lung cancer patientsAndrea S Fung, Karen Kopciuk, Michelle L Dean, et al.
Metabolomics : Official Journal of the Metabolomic Society|April 14, 2016
Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatmentDesirée Hao, M Omair Sarfaraz, Farshad Farshidfar, et al.
Lung Cancer (Amsterdam, Netherlands)|July 20, 2019
Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based studyAmanda J W Gibson, Haocheng Li, Adrijana D'Silva, et al.
The Oncologist|September 30, 2024
Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancerJaime Shaw, Xerxes Pundole, Akhila Balasubramanian, et al.
Medical Oncology (Northwood, London, England)|August 4, 2018
Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancerAmanda Jane Williams Gibson, Haocheng Li, Adrijana D'Silva, et al.
Lung Cancer (Amsterdam, Netherlands)|June 12, 2024
Natural history of SCLC patients treated in third-line and beyond: A retrospective real world studyHossein Borghaei, Xerxes Pundole, Laura Sangaré, et al.
British Journal of Cancer|April 19, 2020
Correction: Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cellsNicholas R Jette, Suraj Radhamani, Greydon Arthur, et al.
Pageof 3